RNA
Atrium Therapeutics, Inc.
$12.15
-0.01
(-0.08%)
Mkt Cap
207.83M
Volume
122,260
52W Range
11.4-16.77
Sector
Healthcare
Beta
0.19
EPS (TTM)
-4.48
P/E Ratio
-3.29
Revenue (TTM)
18.62M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 |
|---|---|
| Revenue | 18.62M |
| Net Income | (76.68M) |
| EPS | -4.48 |
| Free Cash Flow | (42.57M) |
| FCF / Share | -2.49 |
| Operating CF | (41.13M) |
| Total Assets | 278.35M |
| Total Debt | 3.67M |
| Cash & Equiv | 270.00M |
| Book Value | 207.29M |
| Return on Equity | -0.37 |
| Metric | Q1 2026 | Q4 2025 |
|---|---|---|
| Revenue | 19.64M | 859,000 |
| Net Income | (16.63M) | (48.07M) |
| EPS | -0.97 | -1.70 |
| Free Cash Flow | (33.24M) | (20.13M) |
| FCF / Share | -1.94 | -1.18 |
| Operating CF | (31.14M) | (19.25M) |
| Total Assets | 292.36M | 278.35M |
| Total Debt | 2.68M | 3.67M |
| Cash & Equiv | 267.85M | 270.00M |
| Book Value | 234.10M | 207.29M |
| Return on Equity | -0.07 | -0.23 |
RNA News
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1